share_log

中国再生医学(08158.HK):2023年股东应占亏损约1.08亿港元

China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023

Gelonghui Finance ·  Apr 1 20:04

On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment